Semax

Typically administered intranasally. Standard research dosing is 300-600 mcg/day divided into 2-3 doses, with advanced protocols up to 900 mcg/day. Russian clinical formulations include 0.1% and 1% intranasal solutions. Cycles commonly range from 10-30 days. Also available as subcutaneous injection. Crosses the blood-brain barrier effectively via nasal route.

Rapidly elevates brain-derived neurotrophic factor (BDNF) levels and TrkB receptor expression in the hippocampus, promoting neuronal survival and synaptic plasticity.

Activates dopaminergic and serotonergic brain systems in rodent models, influencing mood, attention, and motivation.

Inhibits enzymes involved in the degradation of enkephalins and other endogenous regulatory peptides, potentially modulating pain and stress responses.

Modulates gene expression following cerebral ischemia-reperfusion, reducing neuronal damage and promoting recovery.

Improves attention, memory formation, and learning capacity in both animal models and limited human studies, primarily conducted in Russia.

Used clinically in Russia for stroke recovery; shown to reduce neuronal damage in ischemic models.

May reduce anxiety without the sedation associated with benzodiazepines, possibly through modulation of serotonergic pathways.

Preliminary evidence suggests potential benefit for attention-deficit hyperactivity disorder symptoms.

Therapeutic peptides are emerging as promising adjuncts in the management of orthopaedic injuries, g...

Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · Omar F Rahman, Steven J Lee, William A Seeds

Lysosomal membrane permeabilization (LMP) is exacerbated following spinal cord injury (SCI), leading...

British journal of pharmacology · Rongjie Liu, Yituo Chen, Haosheng Huang, Xiang Li, Junlei Lv

Alzheimer's disease, first described over a century ago, is currently among the most common neurodeg...

Acta naturae · A I Radchenko, E V Kuzubova, A A Apostol, V A Mitkevich, L A...

Current antidepressant therapy shows substantial limitations, and there is an urgent need for the de...

European journal of pharmacology · Ludmila S Inozemtseva, Ksenia A Yatsenko, Natalya Yu Glazova...

Alzheimer's disease, the most common form of dementia, is characterized by the aggregation of amyloi...

ACS chemical neuroscience · Michele F M Sciacca, Irina Naletova, Maria Laura Giuffrida, ...